Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
4 ]! P' |; K9 g, s7 U! X& ^+ ^NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 , O. c/ ~. S/ Q7 e6 p
+ Author Affiliations
( ]1 z6 f9 V/ j; G4 s4 I$ ?% m
$ \' F' \: s$ {+ @, Q' U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
9 E+ d) f% J; F) [/ S: G+ j0 f2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
& q8 s: h8 y; s$ @ g7 q3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 8 B" O* _! \; s6 z+ V
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
. ~* q; h/ |- C; J4 [5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
6 e0 V: f$ `7 a( p" Y& V" E, `9 {6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
7 l# z( A% Z2 U0 Y7 |1 A0 K$ \8 b7Kinki University School of Medicine, Osaka 589-8511, Japan 1 g8 b% Q& h1 Y
8Izumi Municipal Hospital, Osaka 594-0071, Japan 2 D2 p% m3 ^! c6 N' U
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
) r' K: S! `( \2 p, @4 @0 \Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
+ w% F5 v% c h4 w. q+ _6 L6 G; ~AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
6 @# m3 [- X# w ?& O P% x3 ^
# x. Z7 h' m, g/ o; {; K |